Arcus Biosciences Appoints Kristen M. Hege, M.D., to its Board of Directors
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced the appointment of Kristen M. Hege, M.D., to its Board of Directors. Dr. Hege brings more than 20 years of oncology clinical leadership experience to Arcus’s board.
“We are thrilled to welcome Dr. Hege to our Board of Directors,” said Terry Rosen, Ph.D., Chief Executive Officer at Arcus. “Dr. Hege brings extensive and highly relevant experience in translational medicine and clinical development in oncology to Arcus and has the ideal background to contribute to our Company’s biomarker strategy and clinical development plans. Also, as Dr. Hege has served as a member of our Scientific Advisory Board and as a Board Observer, she is already very familiar with Arcus and knowledgeable on the pathways we are pursuing. We look forward to having access to Dr. Hege’s extraordinary experience, perspectives and wisdom as we expand our clinical development programs and explore opportunities to bring our medicines to cancer patients as rapidly as possible.”
Dr. Hege currently serves as Corporate Vice President, Translational Development, Hematology and Oncology and San Francisco site head at Celgene where she is responsible for translational and early clinical development for all hematology and oncology products including small molecules, biologics and cell therapies. Prior to joining Celgene, she served as acting Chief Medical Officer at Aragon Pharmaceuticals, Theraclone Sciences and Cellerant Therapeutics. Dr. Hege began her career at Cell Genesys Inc. where she spent 14 years in various roles of increasing responsibility, ultimately leading the Clinical Research and Development organization.
Dr. Hege is currently a Clinical Professor of Medicine, Hematology and Oncology and an attending physician at the University of California, San Francisco (UCSF). She has held a clinical faculty appointment at UCSF since 1997 in the adult hematology and bone marrow transplant program. Dr. Hege has been board-certified in internal medicine, medical oncology and hematology. Dr. Hege received her B.A. summa cum laude from Dartmouth, M.D. from UCSF, and completed a medical residency at Brigham & Women's Hospital, Harvard Medical School and a fellowship in hematology and oncology at UCSF. She serves on the Board of Directors of the Society for Immunotherapy of Cancer and Mersana Therapeutics and the Strategic Advisory Group for the Parker Institute for Cancer Immunotherapy. In 2015, FierceBiotech recognized her as one of the top 12 women in Biopharma.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies. Arcus has several programs targeting important immuno-oncology pathways, including a dual adenosine receptor antagonist AB928, which is in a Phase 1/1b program to evaluate AB928 in combination with other agents in multiple tumor types, and an anti-PD-1 antibody AB122, which is being evaluated in a Phase 1 trial and is being tested in combination with Arcus’s other product candidates. Arcus’s other programs include AB154, an anti-TIGIT antibody, which is in a Phase 1 trial to evaluate AB154 as monotherapy and in combination with AB122, and AB680, a small molecule inhibitor of CD73, which is in IND-enabling studies. Arcus has extensive in-house expertise in medicinal chemistry, immunology, biochemistry, pharmacology and structural biology. For more information about Arcus Biosciences, please visit www.arcusbio.com.
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including, but not limited to, the scope and pace of Arcus’s clinical development efforts, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause Arcus’s actual results, performance or achievements to differ significantly from those expressed or implied. Factors that could cause or contribute to such differences include, but are not limited to, the inherent uncertainty associated with pharmaceutical product development and clinical trials, including unexpected safety data observed during our clinical trials, changes in expected or existing competition, difficulties or delays in the initiation and enrollment of our clinical trials and changes in the regulatory environment. Risks and uncertainties facing Arcus are described more fully in Arcus’s quarterly report on Form 10-Q for the quarter ended June 30, 2018 filed on August 6, 2018 with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Arcus disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181022005262/en/